Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM501 Phase I in Advanced HER2-Aberrant Solid Tumors
NCT05804864Phase 1Not yet recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of km501 in solid tumor (advanced stage), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Recommended Phase 2 Dose at 4 weeks and 2 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
km501
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05804864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804864.